Related Experiment Video
Updated: May 25, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Optimal dose of contrast medium for depiction of hypervascular HCC on dynamic MDCT
Tetsuya Fujigai1, Seishi Kumano, Masahiro Okada
1Department of Radiology, Kinki University School of Medicine, Osakasayama City, Osaka 589-8511, Japan. tetuyafu2000@yahoo.co.jp
Insights
A higher dose of contrast medium (630 mgI/kg) significantly improves the visualization of hypervascular hepatocellular carcinoma (HCC) during dynamic MDCT scans. This optimal dose enhances tumor-liver contrast and hepatic enhancement across all phases.
Area of Science:
- Radiology
- Medical Imaging
- Hepatobiliary Imaging
Background:
- Hepatocellular carcinoma (HCC) is a common primary liver malignancy.
- Accurate depiction of hypervascular HCC is crucial for diagnosis and treatment planning.
- Dynamic multidetector-row computed tomography (MDCT) is a key imaging modality for HCC evaluation.
Purpose of the Study:
- To determine the optimal contrast medium dose for visualizing hypervascular HCC.
- To evaluate contrast enhancement during hepatic arterial phase (HAP), portal venous phase (PVP), and delayed phase (DP) of dynamic MDCT.
- To compare the efficacy of two different contrast doses (525 mgI/kg vs. 630 mgI/kg).
Main Methods:
- Prospective study involving 128 patients with 56 hypervascular HCCs.
- Patients randomized to receive either 525 mgI/kg (Protocol A) or 630 mgI/kg (Protocol B) of contrast medium.
- Measurements included attenuation values of aorta, portal vein, hepatic vein, parenchyma, and HCC; tumor-liver contrast (TLC) was calculated.
Main Results:
- Protocol B (630 mgI/kg) yielded significantly higher aortic attenuation values across all phases (P<0.01).
- Hepatic enhancement was significantly greater with Protocol B compared to Protocol A during all phases (P<0.01).
- Tumor-liver contrast was significantly higher with Protocol B during the HAP (P=0.042).
Conclusions:
- A contrast dose of 630 mgI/kg significantly improves hypervascular HCC depiction during HAP.
- This higher dose ensures sufficient hepatic enhancement (≥50 HU) during the delayed phase.
- The findings support 630 mgI/kg as the optimal dose for dynamic MDCT evaluation of hypervascular HCC.
Purpose:
The purpose of this study is to prospectively investigate the optimal dose of contrast medium for the depiction of hypervascular hepatocellular carcinoma (HCC) during the hepatic arterial phase (HAP), portal venous phase (PVP) and delayed phase (DP) of dynamic MDCT.
Materials And Methods:
The study included 128 patients, out of these patients, 36 patients were found to have 56 hypervascular HCCs. Sixty-three patients were assigned to receive a dose of 525 mgI/kg with protocol A, and 62 received a dose of 630 mgI/kg with protocol B. Measurements of the attenuation values of the abdominal aorta, portal vein, hepatic vein, hepatic parenchyma and HCC during the HAP, PVP and DP were taken. Tumor-liver contrast (TLC) was calculated from the attenuation value of the hepatic parenchyma and HCC.
Results:
The aortic attenuation value with protocol B (351, 166, and 132 HU) was significantly higher than that with protocol A (313, 153, and 120 HU) during all the phases, (P<0.01 for all phases). The hepatic enhancement from unenhanced baseline with protocol B (25.2, 63.6, 50.6 HU) was significantly higher than that with protocol A (20.2, 55.1 and 43.0 HU) during all the phases, (P<0.01 for all phases). The TLC with protocol B (37.4, -11.8 and -13.6 HU) was significantly higher than that with protocol A (28.0, -9.8 and -12.1 HU) during HAP (P=0.042).
Conclusion:
The administration of 630 mgI/kg of body weight depicts hypervascular HCC more clearly during HAP and shows sufficient hepatic enhancement of 50 HU during DP.
More Related Videos
08:13In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
Related Concept Videos
Imaging Studies III: Computed Tomography
Radiological Investigation I: X-ray and CT
Imaging Studies for Cardiovascular System V: CT
Imaging Studies VII: Vascular Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...